MSOS ETF outlook: high volatility and cannabis rescheduling uncertainty. Top-heavy holdings face 280E risk; DEA hearing is ...

The AdvisorShares Pure US Cannabis ETF is rated a buy, driven by real regulatory progress and potential further catalysts.

The DEA's cannabis rescheduling hearing runs through a July 15 deadline, putting cannabis stocks and the MSOS ETF in focus.

Trulieve Cannabis Corp. and Green Thumb Industries were named to Time magazine’s America’s Best Companies 2026 list.

It may not be the American Dream per se, but the universe of cannabis exchange-traded funds got much more American Wednesday with the debut of the AdvisorShares Pure US Cannabis ETF (NYSE: MSOS). What ...

The MSOS cannabis ETF hit a 2026 high ahead of the DEA's July 15 rescheduling deadline, as Trulieve, Curaleaf and Canopy Growth reshape the sector.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Federal law still regards cannabis as a Schedule I controlled substance, and neither major-party presidential candidate — U.S. President Donald Trump and former Vice President Joe Biden — supports ...

Will the rescheduling of cannabis fuel a boom in cannabis stocks? Analysts from Z&A delve into the pros and cons of MSOs and cannabis rescheduling in their latest equity research report. Re-scheduling ...

Investors in Advisorshares Trust Advisorshares Pure US Cannabis (Symbol: MSOS) saw new options begin trading today, for the February 25th expiration. At Stock Options Channel, our YieldBoost formula ...